16 March 2017
Mainstay Medical Announces Date for Full Year Results
Dublin – Ireland – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), announces that it will release its 2016 Full Year Results on Thursday 23 March 2017 at 07:00am GMT.
Peter Crosby, Chief Executive Officer and Hugh Kavanagh, Chief Financial Officer, will host a conference call and Q&A for analysts and investors at 12:30pm GMT (1:30pm CET, 8:30am EST) on the day. The call will be conducted in English and a replay will be available for 30 days.
Dial-ins for the call are outlined below:
Europe: + 44 203 139 4830
Ireland: + 353 1 696 8154
France: + 33 2 9092 0977
USA: + 1 718 873 9077
Participant PIN: 75508149#
The results press release will be available on the “Investors” section of the Mainstay Medical website at: http://www.mainstay-medical.com/en/investors
During the conference call, there will be an opportunity to ask questions. Instructions for this will be provided at the start of the call. Questions for the conference call are welcomed in advance via e-mail to firstname.lastname@example.org
Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).
About chronic low back pain
One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstay-medical.com
CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.
PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
Tel: +44 203 709 5700 / +44 7921 697 654
FTI Consulting (for Ireland)
Jonathan Neilan Tel: +353 1 663 3686
NewCap (for France)
Tel: +33 1 44 71 20 40
Tel: +49 2102 1485368
LifeSci Advisors, LLC
Tel: + 1 (212) 915-2578